Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1997 Feb;73(856):75–80. doi: 10.1136/pgmj.73.856.75

Ursodeoxycholic acid in the treatment of liver diseases.

S Saksena 1, R K Tandon 1
PMCID: PMC2431224  PMID: 9122101

Abstract

Ursodeoxycholic acid is a dihydroxy bile acid with a rapidly expanding spectrum of usage in acute and chronic liver diseases. The various mechanisms of action of this hydrophilic bile acid include direct cytoprotection, detergent action on dysfunctional microtubules, immunomodulation and induction of hypercholeresis. Its efficacy in primary biliary cirrhosis and primary sclerosing cholangitis as an adjunct to medical therapy has been well established. Newer indications include its use in the management of chronic hepatitis, cirrhosis, post liver transplant rejection, graft-versus-host disease and acute viral hepatitis, where it not only relieves symptoms of cholestasis but also arrests ongoing hepatocyte necrosis.

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batta A. K., Salen G., Mirchandani R., Tint G. S., Shefer S., Batta M., Abroon J., O'Brien C. B., Senior J. R. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol. 1993 May;88(5):691–700. [PubMed] [Google Scholar]
  2. Battezzati P. M., Podda M., Bianchi F. B., Naccarato R., Orlandi F., Surrenti C., Pagliaro L., Manenti F. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J Hepatol. 1993 Mar;17(3):332–338. doi: 10.1016/s0168-8278(05)80214-4. [DOI] [PubMed] [Google Scholar]
  3. Bellentani S., Tabarroni G., Barchi T., Ferretti I., Fratti N., Villa E., Manenti F. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial. J Hepatol. 1989 Jan;8(1):7–12. doi: 10.1016/0168-8278(89)90155-4. [DOI] [PubMed] [Google Scholar]
  4. Beuers U., Nathanson M. H., Boyer J. L. Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology. 1993 Feb;104(2):604–612. doi: 10.1016/0016-5085(93)90433-d. [DOI] [PubMed] [Google Scholar]
  5. Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., Weinzierl M., Pape G. R., Sauerbruch T., Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992 Sep;16(3):707–714. doi: 10.1002/hep.1840160315. [DOI] [PubMed] [Google Scholar]
  6. Bouscarel B., Fromm H., Ceryak S., Cassidy M. M. Ursodeoxycholic acid increases low-density lipoprotein binding, uptake and degradation in isolated hamster hepatocytes. Biochem J. 1991 Dec 15;280(Pt 3):589–598. doi: 10.1042/bj2800589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bouscarel B., Fromm H., Nussbaum R. Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes. Am J Physiol. 1993 Feb;264(2 Pt 1):G243–G251. doi: 10.1152/ajpgi.1993.264.2.G243. [DOI] [PubMed] [Google Scholar]
  8. Bouscarel B., Gettys T. W., Fromm H., Dubner H. Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC. Am J Physiol. 1995 Feb;268(2 Pt 1):G300–G310. doi: 10.1152/ajpgi.1995.268.2.G300. [DOI] [PubMed] [Google Scholar]
  9. Buongiorno G., Quaranta G. M., Guerra V., Misciagna G., Manghisi O. G. Studio dei fattori che influenzano l'effetto della terapia con acido ursodesossicolico nelle ipertransaminasemie croniche. Recenti Prog Med. 1992 May;83(5):298–302. [PubMed] [Google Scholar]
  10. Buzzelli G., Moscarella S., Focardi G., Dattolo P., Giusti A., Calviani L., Relli P., Gentilini P. L'emisuccinato dell'acido ursodesossicolico nel trattamento dell'epatite cronica attiva. Studio clinico-terapeutico controllato. Minerva Med. 1992 Sep;83(9):537–540. [PubMed] [Google Scholar]
  11. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990 Jan;11(1):12–15. doi: 10.1002/hep.1840110104. [DOI] [PubMed] [Google Scholar]
  12. Chazouillères O., Poupon R., Capron J. P., Metman E. H., Dhumeaux D., Amouretti M., Couzigou P., Labayle D., Trinchet J. C. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990 Jul;11(1):120–123. doi: 10.1016/0168-8278(90)90281-u. [DOI] [PubMed] [Google Scholar]
  13. Crosignani A., Battezzati P. M., Setchell K. D., Camisasca M., Bertolini E., Roda A., Zuin M., Podda M. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology. 1991 Feb;13(2):339–344. [PubMed] [Google Scholar]
  14. Crosignani A., Podda M., Battezzati P. M., Bertolini E., Zuin M., Watson D., Setchell K. D. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology. 1991 Dec;14(6):1000–1007. [PubMed] [Google Scholar]
  15. Fedorowski T., Salen G., Calallilo A., Tint G. S., Mosbach E. H., Hall J. C. Metabolism of ursodeoxycholic acid in man. Gastroenterology. 1977 Nov;73(5):1131–1137. [PubMed] [Google Scholar]
  16. Ferrara J. L., Deeg H. J. Graft-versus-host disease. N Engl J Med. 1991 Mar 7;324(10):667–674. doi: 10.1056/NEJM199103073241005. [DOI] [PubMed] [Google Scholar]
  17. Fried R. H., Murakami C. S., Fisher L. D., Willson R. A., Sullivan K. M., McDonald G. B. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med. 1992 Apr 15;116(8):624–629. doi: 10.7326/0003-4819-116-8-624. [DOI] [PubMed] [Google Scholar]
  18. Friman S., Persson H., Scherstén T., Svanvik J., Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc. 1992 Feb;24(1):389–390. [PubMed] [Google Scholar]
  19. Friman S., Svanvik J. A possible role of ursodeoxycholic acid in liver transplantation. Scand J Gastroenterol Suppl. 1994;204:62–64. doi: 10.3109/00365529409103627. [DOI] [PubMed] [Google Scholar]
  20. Fromm H., Carlson G. L., Hofmann A. F., Farivar S., Amin P. Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids. Am J Physiol. 1980 Sep;239(3):G161–G166. doi: 10.1152/ajpgi.1980.239.3.G161. [DOI] [PubMed] [Google Scholar]
  21. Fromm H., Sarva R. P., Bazzoli F. Formation of ursodeoxycholic acid from chenodeoxycholic acid in the human colon: studies of the role of 7-ketolithocholic acid as an intermediate. J Lipid Res. 1983 Jul;24(7):841–853. [PubMed] [Google Scholar]
  22. García Villarreal L., Zozaya J. M., Macías E., García González N., Quiroga J., Conchillo F., Prieto J. Tratamiento de la cirrosis biliar primaria con ácido ursodesoxicólico. Resultados a corto y medio plazo y relación con el estudio de la enfermedad. Rev Esp Enferm Dig. 1991 Nov;80(5):311–315. [PubMed] [Google Scholar]
  23. Güldütuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology. 1993 Jun;104(6):1736–1744. doi: 10.1016/0016-5085(93)90653-t. [DOI] [PubMed] [Google Scholar]
  24. Hayashi H., Higuchi T., Ichimiya H., Hishida N., Sakamoto N. Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid. Gastroenterology. 1990 Aug;99(2):533–535. doi: 10.1016/0016-5085(90)91038-8. [DOI] [PubMed] [Google Scholar]
  25. Heuman D. M., Mills A. S., McCall J., Hylemon P. B., Pandak W. M., Vlahcevic Z. R. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology. 1991 Jan;100(1):203–211. doi: 10.1016/0016-5085(91)90602-h. [DOI] [PubMed] [Google Scholar]
  26. Hwang S. J., Chan C. Y., Lee S. D., Wu J. C., Tsay S. H., Lo K. J. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J Gastroenterol Hepatol. 1993 May-Jun;8(3):217–223. doi: 10.1111/j.1440-1746.1993.tb01189.x. [DOI] [PubMed] [Google Scholar]
  27. Kao J. H., Lai M. Y., Lin J. T., Yang P. M., Sheu J. C., Chen D. S., Sung J. L., Wang T. H. Therapeutic effect of ursodeoxycholic acid on early-stage primary biliary cirrhosis. J Formos Med Assoc. 1991 Oct;90(10):970–974. [PubMed] [Google Scholar]
  28. Kitani K., Kanai S. Tauroursodeoxycholate prevents taurocholate induced cholestasis. Life Sci. 1982 Feb 7;30(6):515–523. doi: 10.1016/0024-3205(82)90264-8. [DOI] [PubMed] [Google Scholar]
  29. Knapp A. B., Crawford J. M., Rappeport J. M., Gollan J. L. Cirrhosis as a consequence of graft-versus-host disease. Gastroenterology. 1987 Feb;92(2):513–519. doi: 10.1016/0016-5085(87)90150-8. [DOI] [PubMed] [Google Scholar]
  30. Knyrim K., Vakil N., Pfab R., Classen M. The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man. Hepatology. 1989 Aug;10(2):134–142. doi: 10.1002/hep.1840100203. [DOI] [PubMed] [Google Scholar]
  31. Leuschner U., Fischer H., Kurtz W., Güldütuna S., Hübner K., Hellstern A., Gatzen M., Leuschner M. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989 Nov;97(5):1268–1274. doi: 10.1016/0016-5085(89)91698-3. [DOI] [PubMed] [Google Scholar]
  32. Lindor K. D., Dickson E. R., Baldus W. P., Jorgensen R. A., Ludwig J., Murtaugh P. A., Harrison J. M., Wiesner R. H., Anderson M. L., Lange S. M. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994 May;106(5):1284–1290. doi: 10.1016/0016-5085(94)90021-3. [DOI] [PubMed] [Google Scholar]
  33. Lirussi F., Okolicsanyi L. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease. Ital J Gastroenterol. 1992 Jan;24(1):31–35. [PubMed] [Google Scholar]
  34. Ludwig J., LaRusso N. F., Wiesner R. H. The syndrome of primary sclerosing cholangitis. Prog Liver Dis. 1990;9:555–566. [PubMed] [Google Scholar]
  35. Malavolti M., Fromm H., Ceryak S., Roberts I. M. Modulation of low density lipoprotein receptor activity by bile acids: differential effects of chenodeoxycholic and ursodeoxycholic acids in the hamster. J Lipid Res. 1987 Nov;28(11):1281–1295. [PubMed] [Google Scholar]
  36. Matsuzaki Y., Tanaka N., Osuga T., Aikawa T., Shoda J., Doi M., Nakano M. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol. 1990 Jan;85(1):15–23. [PubMed] [Google Scholar]
  37. Mazzella G., Parini P., Bazzoli F., Villanova N., Festi D., Aldini R., Roda A., Cipolla A., Polimeni C., Tonelli D. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci. 1993 May;38(5):896–902. doi: 10.1007/BF01295917. [DOI] [PubMed] [Google Scholar]
  38. Mekhjian H. S., Phillips S. F., Hofmann A. F. Colonic absorption of unconjugated bile acids: perfusion studies in man. Dig Dis Sci. 1979 Jul;24(7):545–550. doi: 10.1007/BF01489324. [DOI] [PubMed] [Google Scholar]
  39. O'Brien C. B., Senior J. R., Arora-Mirchandani R., Batta A. K., Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 1991 Nov;14(5):838–847. doi: 10.1002/hep.1840140516. [DOI] [PubMed] [Google Scholar]
  40. Oka H., Toda G., Ikeda Y., Hashimoto N., Hasumura Y., Kamimura T., Ohta Y., Tsuji T., Hattori N., Namihisa T. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn. 1990 Dec;25(6):774–780. doi: 10.1007/BF02779195. [DOI] [PubMed] [Google Scholar]
  41. Ouyang A., Sunshine A. G., Reynolds J. C. Caloric content of a meal affects duration but not contractile pattern of duodenal motility in man. Dig Dis Sci. 1989 Apr;34(4):528–536. doi: 10.1007/BF01536328. [DOI] [PubMed] [Google Scholar]
  42. Palma J., Reyes H., Ribalta J., Iglesias J., Gonzalez M. C., Hernandez I., Alvarez C., Molina C., Danitz A. M. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology. 1992 Jun;15(6):1043–1047. doi: 10.1002/hep.1840150612. [DOI] [PubMed] [Google Scholar]
  43. Parquet M., Metman E. H., Raizman A., Rambaud J. C., Berthaux N., Infante R. Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man. Eur J Clin Invest. 1985 Aug;15(4):171–178. doi: 10.1111/j.1365-2362.1985.tb00164.x. [DOI] [PubMed] [Google Scholar]
  44. Perdigoto R., Wiesner R. H. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology. 1992 Apr;102(4 Pt 1):1389–1391. [PubMed] [Google Scholar]
  45. Pisciotta G., Scialabba A., Montalto G., Di Marco C., Fontana N., Ruggeri I., Sausa F., Bracco S., Notarbartoló A. L'acido ursodesossicolico nel trattamento delle malattie croniche di fegato. Risultati a breve termine. Minerva Gastroenterol Dietol. 1991 Jan-Mar;37(1):29–33. [PubMed] [Google Scholar]
  46. Poupon R. E., Chrétien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology. 1993 Apr;17(4):599–604. doi: 10.1002/hep.1840170412. [DOI] [PubMed] [Google Scholar]
  47. Rolandi E., Franceschini R., Cataldi A., Cicchetti V., Carati L., Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur J Clin Pharmacol. 1991;40(5):473–476. doi: 10.1007/BF00315225. [DOI] [PubMed] [Google Scholar]
  48. Shibata J., Fujiyama S., Honda Y., Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J Gastroenterol Hepatol. 1992 May-Jun;7(3):277–282. doi: 10.1111/j.1440-1746.1992.tb00980.x. [DOI] [PubMed] [Google Scholar]
  49. Stiehl A., Raedsch R., Rudolph G. Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology. 1988 May;94(5 Pt 1):1201–1206. doi: 10.1016/0016-5085(88)90013-3. [DOI] [PubMed] [Google Scholar]
  50. Stiehl A., Rudolph G., Raedsch R., Möller B., Hopf U., Lotterer E., Bircher J., Fölsch U., Klaus J., Endele R. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology. 1990 Sep;12(3 Pt 1):492–497. doi: 10.1002/hep.1840120308. [DOI] [PubMed] [Google Scholar]
  51. Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W. J., Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. 1994 Jan;20(1):57–64. doi: 10.1016/s0168-8278(05)80467-2. [DOI] [PubMed] [Google Scholar]
  52. Terasaki S., Nakanuma Y., Ogino H., Unoura M., Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol. 1991 Sep;86(9):1194–1199. [PubMed] [Google Scholar]
  53. Turner I. B., Myszor M., Mitchison H. C., Bennett M. K., Burt A. D., James O. F. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol. 1994 Mar-Apr;9(2):162–168. doi: 10.1111/j.1440-1746.1994.tb01237.x. [DOI] [PubMed] [Google Scholar]
  54. Ward A., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1984 Feb;27(2):95–131. doi: 10.2165/00003495-198427020-00001. [DOI] [PubMed] [Google Scholar]
  55. Wiesner R. H., Ludwig J., Krom R. A., Hay J. E., van Hoek B. Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment. Mayo Clin Proc. 1993 Jan;68(1):69–79. doi: 10.1016/s0025-6196(12)60022-6. [DOI] [PubMed] [Google Scholar]
  56. Yoon Y. B., Hagey L. R., Hofmann A. F., Gurantz D., Michelotti E. L., Steinbach J. H. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology. 1986 Apr;90(4):837–852. doi: 10.1016/0016-5085(86)90859-0. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES